 | Genomics and Infectious Diseases UC San Francisco presents Mini Medical School. In this edition, Joe DeRisi, Howard Hughes Medical Institute Investigator at UCSF, explores the need to detect and contain diseases quickly. Learn about the hunt for emerging viruses such as SARS, the characterization of the malaria parasite, and how this work can translate into new drugs and vaccines. Series: "UCSF Mini Medical School for the Public" [11/2006] [Health and Medicine] [Show ID: 11801] |
 | Perioperative care Perioperative care |
 | The Fight Against Infectious Diseases: Partnership in Health Infectious diseases cause more than 14 million deaths every year, the majority in developing countries. See how new partnership mechanisms can improve access to vaccines, drugs and other goods needed to control communicable diseases. |
 | Advances in Infectious Disease Vaccines New vaccines help protect against infectious diseases such as shingles and human papillomavirus. While shingles typically displays obvious symptoms, HPV often does not. Learn why it is now more important than ever to vaccinate for smallpox, a highly contagious disease caused by the variola virus that kills 30 percent of unvaccinated people. |
 | Electron Transport animation Electron Transport animation |
 | HEAVEN SHALL BURN - Endzeit HEAVEN SHALL BURN - Endzeit. From the album "Iconoclast (pt. 1 the final resistance)" century media 2008. |
 | Basic Body Structure Basic Body Structure |
 | Jaundice jaundice |
 | non infectious disease project for health class |
 | The Next Big Stock (AEMD) Aethlon Medical has developed a first-in-class medical device to assist in the treatment of infectious disease. The device, known as the Hemopurifier®, is positioned to be a broad-spectrum treatment for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). On March 6, 2007, Aethlon submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to initiate human safety studies of the Aethlon Hemopurifier® as a treatment countermeasure against select category "A" bioterror threats. Additional studies to demonstrate utility of the Hemopurifier® as a countermeasure against bioterror threats are being conducted with researchers at The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Category "A" bioterror threats are defined by the CDC as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; may cause public panic and social disruption, and require special action for public health preparedness. Global researcher, Frost & Sullivan, awarded the Hemopurifier® the 2006 Technology Innovation Award, and The AIDS Institute presented Aethlon with the 2007 Innovative HIV Life Sciences Leadership Award. The Company has also initiated research on a second generation Hemopurifier® that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com. NOT PUBLISHED BY AETHLON MEDICAL |
| Oceanfrontier Hideaway | |
| Sheraton Suites Philadelphia Airport | |
| The Boulders Resort and Golden Door Spa | |
| Coral Beach Club |
العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
Español
